BNZ 1Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40
Latest Information Update: 08 Aug 2016
At a glance
- Originator Bioniz
- Developer Bioniz; National Institutes of Health (USA)
- Class Peptides
- Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I T-cell leukaemia; Tropical spastic paraparesis